Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 21 to 30 of 604 total matches.
Addendum: Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
Addendum: Drugs for Depression ...
In our article on Drugs for Depression, we should have
included tardive dyskinesia (TD) in our list of adverse
effects of second-generation antipsychotic (SGA) drugs.
TD, which is more commonly associated with first-generation-
antipsychotics, can also occur in patients
taking an SGA, especially with prolonged use. A metaanalysis
found that the annualized incidence of TD was
2.6% in SGA users (M Carbon et al. World Psychiatry 2018;
17:330). Older adults are at increased risk.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):24 doi:10.58347/tml.2024.1695e | Show Introduction Hide Introduction
Drugs for Postmenopausal Osteoporosis
The Medical Letter on Drugs and Therapeutics • Jul 08, 2024 (Issue 1706)
Drugs for Postmenopausal Osteoporosis ...
Pharmacologic treatment is recommended for
postmenopausal women who have bone density
T-scores (standard deviations from normal mean
values in the spine, femoral neck, total hip, or distal
radius) of -2.5 or below, T-scores between -1.0 and
-2.5 with a history of fragility (low-trauma) fracture
of the hip or spine, or T-scores between -1.0 and
-2.5 with a FRAX 10-year probability of ≥3% for hip
fracture or ≥20% for major osteoporotic fracture.
Med Lett Drugs Ther. 2024 Jul 8;66(1706):105-12 doi:10.58347/tml.2024.1706a | Show Introduction Hide Introduction
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
Drugs for Menopausal Symptoms ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Drugs for Head Lice
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
Drugs for Head Lice ...
Pediculosis capitis (head lice infestations) occur in
all age groups, but especially in elementary school
children. In most cases, transmission occurs by
head-to-head contact. Pharmacologic treatment is
recommended for persons with live lice or eggs (nits)
within 1 cm of the scalp. Topical pediculicides should
be tried first. Oral therapy is occasionally required for
refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92 doi:10.58347/tml.2024.1704a | Show Introduction Hide Introduction
Table: Some Drug Interactions with Drugs for IBD (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Table: Some Drug Interactions with Drugs for IBD (online only) ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114 doi:10.58347/tml.2023.1680c | Show Introduction Hide Introduction
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
Drugs for Opioid Use Disorder ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
Drugs and Devices for Weight Management ...
Overweight is generally defined as a body mass
index (BMI) between 25 and 29.9 kg/m2 in adults. A
BMI ≥30 is considered obese (criteria differ slightly in
Asian patients). In patients with an elevated BMI, a
5-10% reduction in weight has been associated with
a reduction in the risk of developing type 2 diabetes,
hypertension, and dyslipidemia. Diet, exercise, and
behavior modification are the traditional methods
for losing weight, but they are often inadequate; the
American College of Cardiology no longer recommends
that all patients try lifestyle modification alone before
adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8 doi:10.58347/tml.2025.1734a | Show Introduction Hide Introduction
Drugs for Cognitive Loss and Dementia
The Medical Letter on Drugs and Therapeutics • Aug 22, 2022 (Issue 1657)
Drugs for Cognitive Loss and Dementia ...
Alzheimer's disease (AD) is the most common
cause of dementia, but cognitive decline is also
associated with other neurological conditions such
as Parkinson's disease, dementia with Lewy bodies,
vascular dementia, and frontotemporal dementia.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
Drugs for Irritable Bowel Syndrome ...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating. IBS
is classified by its predominant bowel symptom:
constipation (IBS-C), diarrhea (IBS-D), mixed type
(IBS-M), or unclassified (IBS-U). Since the exact cause
of IBS is unknown, the goal of treatment is symptom
control. Some over-the-counter (OTC) products and
prescription drugs for IBS are listed in Tables 1-4. The
safety of these drugs during pregnancy and lactation
is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24 doi:10.58347/tml.2025.1721a | Show Introduction Hide Introduction
Drugs for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • May 02, 2022 (Issue 1649)
Drugs for Benign Prostatic Hyperplasia ...
About 60% of men ≥60 years old have clinically
relevant prostatic enlargement due to benign prostatic
hyperplasia (BPH). The goals of treatment are to
decrease lower urinary tract symptoms and to prevent
disease progression and complications such as acute
urinary retention. The American Urologic Association's
guidelines for treatment of BPH were recently updated.